218 related articles for article (PubMed ID: 37934596)
1. Dabrafenib protects from cisplatin-induced hearing loss in a clinically relevant mouse model.
Ingersoll MA; Lutze RD; Pushpan CK; Kelmann RG; Liu H; May MT; Hunter WJ; He DZ; Teitz T
JCI Insight; 2023 Dec; 8(24):. PubMed ID: 37934596
[TBL] [Abstract][Full Text] [Related]
2. BRAF inhibition protects against hearing loss in mice.
Ingersoll MA; Malloy EA; Caster LE; Holland EM; Xu Z; Zallocchi M; Currier D; Liu H; He DZZ; Min J; Chen T; Zuo J; Teitz T
Sci Adv; 2020 Dec; 6(49):. PubMed ID: 33268358
[TBL] [Abstract][Full Text] [Related]
3. Repurposing AZD5438 and Dabrafenib for Cisplatin-Induced AKI.
Pushpan CK; Kresock DF; Ingersoll MA; Lutze RD; Keirns DL; Hunter WJ; Bashir K; Teitz T
J Am Soc Nephrol; 2024 Jan; 35(1):22-40. PubMed ID: 37962623
[TBL] [Abstract][Full Text] [Related]
4. FDA-Approved Tedizolid Phosphate Prevents Cisplatin-Induced Hearing Loss Without Decreasing Its Anti-tumor Effect.
Yao Z; Xiao Y; Li W; Kong S; Tu H; Guo S; Liu Z; Ma L; Qiao R; Wang S; Chang M; Zhao X; Zhang Y; Xu L; Sun D; Fu X
J Assoc Res Otolaryngol; 2024 Jun; 25(3):259-275. PubMed ID: 38622383
[TBL] [Abstract][Full Text] [Related]
5. KSR1 Knockout Mouse Model Demonstrates MAPK Pathway's Key Role in Cisplatin- and Noise-induced Hearing Loss.
Ingersoll MA; Lutze RD; Kelmann RG; Kresock DF; Marsh JD; Quevedo RV; Zuo J; Teitz T
J Neurosci; 2024 May; 44(18):. PubMed ID: 38548338
[TBL] [Abstract][Full Text] [Related]
6. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients.
Viglietta V; Shi F; Hu QY; Ren Y; Keilty J; Wolff H; McCarthy R; Kropp J; Weber P; Soglia J
Invest New Drugs; 2020 Oct; 38(5):1463-1471. PubMed ID: 32157599
[TBL] [Abstract][Full Text] [Related]
8. KSR1 knockout mouse model demonstrates MAPK pathway's key role in cisplatin- and noise-induced hearing loss.
Ingersoll MA; Lutze RD; Kelmann RG; Kresock DF; Marsh JD; Quevedo RV; Zuo J; Teitz T
bioRxiv; 2023 Nov; ():. PubMed ID: 38014104
[TBL] [Abstract][Full Text] [Related]
9. FDA-Approved MEK1/2 Inhibitor, Trametinib, Protects Mice from Cisplatin and Noise-Induced Hearing Loss.
Lutze RD; Ingersoll MA; Kelmann RG; Teitz T
bioRxiv; 2024 May; ():. PubMed ID: 38826449
[TBL] [Abstract][Full Text] [Related]
10. An Src-protein tyrosine kinase inhibitor to reduce cisplatin ototoxicity while preserving its antitumor effect.
Bielefeld EC; Tanaka C; Chen GD; Coling D; Li M; Henderson D; Fetoni AR
Anticancer Drugs; 2013 Jan; 24(1):43-51. PubMed ID: 22828384
[TBL] [Abstract][Full Text] [Related]
11. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
Freyer DR; Chen L; Krailo MD; Knight K; Villaluna D; Bliss B; Pollock BH; Ramdas J; Lange B; Van Hoff D; VanSoelen ML; Wiernikowski J; Neuwelt EA; Sung L
Lancet Oncol; 2017 Jan; 18(1):63-74. PubMed ID: 27914822
[TBL] [Abstract][Full Text] [Related]
12. Sodium thiosulfate does not protect ovarian reserve from cisplatin-induced gonadotoxicity†.
So W; Abazarikia A; Zelinski MB; Kim SY
Biol Reprod; 2024 Apr; 110(4):772-781. PubMed ID: 38195246
[TBL] [Abstract][Full Text] [Related]
13. A combinatorial approach to protect sensory tissue against cisplatin-induced ototoxicity.
Febles NK; Bauer MA; Ding B; Zhu X; Gallant ND; Frisina RD
Hear Res; 2022 Mar; 415():108430. PubMed ID: 35051751
[TBL] [Abstract][Full Text] [Related]
14. Molecular Characteristics of Cisplatin-Induced Ototoxicity and Therapeutic Interventions.
Tan WJT; Vlajkovic SM
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003734
[TBL] [Abstract][Full Text] [Related]
15. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Brock PR; Maibach R; Childs M; Rajput K; Roebuck D; Sullivan MJ; Laithier V; Ronghe M; Dall'Igna P; Hiyama E; Brichard B; Skeen J; Mateos ME; Capra M; Rangaswami AA; Ansari M; Rechnitzer C; Veal GJ; Covezzoli A; Brugières L; Perilongo G; Czauderna P; Morland B; Neuwelt EA
N Engl J Med; 2018 Jun; 378(25):2376-2385. PubMed ID: 29924955
[TBL] [Abstract][Full Text] [Related]
16. Evaluating protective and therapeutic effects of alpha-lipoic acid on cisplatin-induced ototoxicity.
Kim KH; Lee B; Kim YR; Kim MA; Ryu N; Jung DJ; Kim UK; Baek JI; Lee KY
Cell Death Dis; 2018 Aug; 9(8):827. PubMed ID: 30068942
[TBL] [Abstract][Full Text] [Related]
17. Sound preconditioning therapy inhibits ototoxic hearing loss in mice.
Roy S; Ryals MM; Van den Bruele AB; Fitzgerald TS; Cunningham LL
J Clin Invest; 2013 Nov; 123(11):4945-9. PubMed ID: 24216513
[TBL] [Abstract][Full Text] [Related]
18. Lovastatin protects against cisplatin-induced hearing loss in mice.
Fernandez K; Spielbauer KK; Rusheen A; Wang L; Baker TG; Eyles S; Cunningham LL
Hear Res; 2020 Apr; 389():107905. PubMed ID: 32062294
[TBL] [Abstract][Full Text] [Related]
19. Mutations in Cockayne Syndrome-Associated Genes (Csa and Csb) Predispose to Cisplatin-Induced Hearing Loss in Mice.
Rainey RN; Ng SY; Llamas J; van der Horst GT; Segil N
J Neurosci; 2016 Apr; 36(17):4758-70. PubMed ID: 27122034
[TBL] [Abstract][Full Text] [Related]
20. Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss.
Hazlitt RA; Teitz T; Bonga JD; Fang J; Diao S; Iconaru L; Yang L; Goktug AN; Currier DG; Chen T; Rankovic Z; Min J; Zuo J
J Med Chem; 2018 Sep; 61(17):7700-7709. PubMed ID: 30091915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
